大摩首予锦欣生殖(1951.HK)“增持”评级目标价11港元
摩根士丹利研究报告指锦欣生殖(01951.HK)是领先的辅助生殖服务提供商,业务遍及中国及美国。公司在成都及深圳分别有两家医院,并有两家厂房。公司2016至2018年的收入及经调整纯利的年复合增长率分别为63%及64%,预期2018至2021年收入及经调整纯利的年复合增长率分别为40%及56%。

报告认为,公司具有长期运营历史和信誉良好的医生;优化运营模式的高生产率;潜在积极的中美协同效应等优势。首次给予其“增持”投资评级,目标价11港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.